$4.66
+0.16 (+3.56%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where EBS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
36 interventional · 11 observational · 21 with posted results
Held by 10 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, Ancora Advisors LLC, AQR CAPITAL MANAGEMENT LLC, D. E. Shaw & Co., Inc., RENAISSANCE TECHNOLOGIES LLC, +5 more) · FINRA short interest 17.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.NCT07268612observationalNumber of individuals who developed inhalational anthrax and/or anthrax meningitis and received CYFENDUS for post exposure prophylaxis divided by the total number reported to have received CYFENDUS for post exposure prophylaxis. | — | Not yet recruiting | Biological: CYFENDUS | Anthrax | 250 | Nov 2036 | ≤ 3,756 d | 2025-12-08 |
| Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure ScenarioNCT02177721Evaluate Clinical Benefit of Raxibacumab for Patients with Symptomatic Inhalational AnthraxOpen-label · Treatment | Phase 4 | Not yet recruiting | Biological: Sample Collection | Infections, Bacterial | 100 | May 2035 | ≤ 3,207 d | 2026-02-06 |
| Observational Study of Raxibacumab in Sporadic Cases of Systemic AnthraxNCT07478471observationalClinical Benefit of Raxibacumab for Patients with Confirmed Systemic Anthrax Disease | — | Not yet recruiting | Biological: Collection of samples | Infections, Bacterial | 10 | May 2030 | ≤ 1,381 d | 2026-03-17 |
| BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric PatientsNCT02051062Margin of PK Equivalence for 90% SurvivalOpen-label · Basic science | Phase 4 | Enrolling by invitation | Biological: Blood sample collection | Botulism | 10 | 2028-07-31 | in 712 d | 2026-01-16 |
| VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia InfectionNCT01374984observationalResolution of vaccinia infection complications | — | Enrolling by invitation | Biological: VIGIV | Complication of Smallpox Vaccination | 100 | Aug 2027 | ≤ 377 d | 2026-05-12 |
| Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic AnthraxNCT03569514observationalAssessment of AIGIV clinical benefit by overall mortality rate | — | Not yet recruiting | Drug: AIGIV | Anthrax | 10 | Jul 2027 | ≤ 346 d | 2026-02-06 |
| A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax PatientsNCT03569553observationalAssessment of AIGIV clinical benefit by overall mortality rate | — | Not yet recruiting | Drug: AIGIV | Inhalational Anthrax | 100 | Jul 2027 | ≤ 346 d | 2026-02-06 |
| Universal Influenza A Vaccine in Healthy AdultsNCT05155319Safety of the UFluA vaccine following one of four dose schedules as evaluated through adverse events (AEs), serious adverse events (SAEs), adverse events of special interest (AESIs) and medically attended adverse events (MAAEs).Randomized · Double-masked · Prevention | Phase 1 | Completed | Biological: UFluA 20 µg each antigen/dose, UFluA 60 µg each antigen/dose, Placebo | Human Influenza | 27 | 2023-10-10actual | — | 2025-01-20 |
| Study of SIAN Nasal Spray in Healthy AdultsNCT05194358Related Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Stabilized Isoamyl Nitrite (SIAN) | Cyanide Poisoning | 47 | 2023-09-29actual | — | 2025-06-03 |
| Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy AdultsNCT05935917PK endpoint - Peak Plasma Concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Brincidofovir | Smallpox | 44 | 2023-08-14actual | — | 2025-01-15 |
| Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy AdultsNCT05377255Mean naloxone plasma concentration AP003 dosing periods.Randomized · Open-label · Treatment | Phase 1 | Completed | Combination product: 16 mg naloxone AP003, 8 mg naloxone NARCAN Nasal Spray | Opioid Overdose | 24 | 2022-05-10actual | — | 2026-08-19 |
| A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected AdultsNCT05142306results2024-05-20Participants With Adverse Events (AEs) up to 72 Hours Post-dosingRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 1 | Completed | Biological: COVID-HIG | SARS-CoV-2 Infection | 23 | 2022-03-28actual | — | 2025-06-08 |
| VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIVNCT02443623results2022-10-26Number of Vaccinated Participants With Adverse Events (AEs) Including Serious Adverse Events (SAEs)Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Biological: Vaccination with ACAM2000 | Smallpox Vaccine Adverse Reaction | 3,032 | Jul 2021actual | — | 2024-03-18 |
| A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy AdultsNCT04661839results2023-02-02Subjects With Adverse Events (AEs) up to 3 Days Post-dosingRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: COVID-HIGIV · Other: Placebo (saline) | COVID-19 | 28 | 2021-07-27actual | — | 2025-06-08 |
| VELOCITY: An Anthrax Vaccine Clinical StudyNCT03877926results2021-12-21Geometric Mean Titer (GMT) of Toxin Neutralizing Antibody (TNA) 50% Neutralization Factor (NF50) at Day 64Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 3 | Completed | Biological: AV7909, BioThrax | Anthrax | 3,689 | 2020-08-06actual | — | 2026-05-06 |
| Velocity 2: An Anthrax Vaccine and Antibiotics Clinical StudyNCT04067011results2021-06-30Ratio of Ciprofloxacin Area Under the Curve From 0 to 12 Hours (AUC0-12h) and Maximum Concentration (Cmax) on Days 8 and 35Randomized · Open-label · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 2 | Completed | Drug: Ciprofloxacin 500Mg Tablet, Doxycycline 100Mg Tablet · Biological: AV7909 | Anthrax | 210 | 2020-03-05actual | — | 2025-09-08 |
| BioThrax® (Anthrax) Vaccine in Pregnancy RegistryNCT01653392observationalPregnancy Outcomes | — | Completed | Biological: Observational Intervention | Pregnancy Complications, Pregnancy Outcome, Congenital Abnormalities | 98 | Feb 2020actual | — | 2024-03-15 |
| Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza ANCT03315104results2020-10-05Frequency Counts and Percentage of Subjects With Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: FLU-IGIV · Other: Placebo for FLU-IGIV | Influenza A H3N2, Influenza A H1N1 | 65 | 2019-06-17actual | — | 2024-03-18 |
| Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)NCT03624946results2020-07-13Number of Subjects With Adverse Events.Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: Zika Virus Immune Globulin (ZIKV-IG) · Other: Placebo | Zika Virus Infection, Zika Virus Disease | 30 | 2019-03-06actual | — | 2024-03-18 |
| ACAM2000® Myopericarditis RegistryNCT01395082observationalThe number of confirmed, probable, suspected, and subclinical cases of myopericarditis, categorized by time since vaccination | — | Completed | — | Myocarditis, Pericarditis | 24 | 2019-02-04actual | — | 2024-03-18 |
| Safety Surveillance Study of ACAM2000® Vaccinia VaccineNCT00927719observationalTo provide information concerning the safety following vaccination with ACAM2000® vaccinia vaccine | — | Completed | Biological: ACAM2000® smallpox vaccine | Smallpox | 897,227 | 2017-12-31actual | — | 2024-03-18 |
| A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047NCT03160339Evaluate safety and tolerability of PXVX0047 by documenting the incidence of severity of solicited adverse eventsRandomized · Triple-masked · Prevention | Phase 1 | Terminatedsponsor's stated reason: Sponsor Decision | Biological: PXVX0047 Vaccine, Teva Ad4/Ad7 Vaccine | Adenoviral Infection | 25 | 2017-11-27actual | — | 2024-03-18 |
| BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum AntitoxinNCT02055183observationalNumber of participants with serious and non-serious adverse events | — | Completed | Drug: BAT | Botulism | 162 | Jul 2017actual | — | 2024-03-15 |
| Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy SubjectsNCT02696291results2018-03-16Number of Subjects Reporting Treatment-emergent Adverse Events (TEAEs) by GroupRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Product development halted for business reasons. | Drug: UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution, UV-4B X mg (dose to be determined) oral solution, UV-4B Y mg (dose to be determined) oral solution, Placebo | Viral Infection | 7 | 2017-03-02actual | — | 2024-03-18 |
| Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected AdultsNCT02771730To evaluate the safety of the Ad4-mgag and Ad4-EnvC150 vaccines in humans when administered via the oral route in combination with an AIDSVAX® B/E boost.Randomized · Double-masked · Prevention | Phase 1 | Terminatedsponsor's stated reason: Study endpoints not met. | Biological: Ad4-mgag, Ad4-EnvC150, AIDSVAX B/E · Other: Placebo Comparator | Healthy Volunteer, HIV Vaccine | 20 | Feb 2017actual | — | 2024-03-18 |
| Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine AdsorbedNCT02339155results2018-01-09Ratio of Geometric Mean Concentrations (GMC) of Anti-protective Antigen (PA) Antibody (Ab) at 4 Weeks (Day 29) After the First AVA Dose (Prior to the Third AVA Dose), Between the AVA Alone and the AVA With Raxibacumab Treatment GroupsRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Biological: AVA, Raxibacumab · Drug: Diphenhydramine | Infections, Bacterial | 573 | 2017-01-03actual | — | 2024-03-18 |
| Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy SubjectsNCT02061358results2016-09-01Subjects With Treatment-emergent Adverse Event (TEAEs) by Treatment GroupRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: UV-4B 3 mg, UV-4B 10 mg, UV-4B 30 mg, UV-4B 90 mg, UV-4B 180 mg, UV-4B 360 mg, UV-4B 720 mg, UV-4B 1000 mg, Placebo | Viral Infection | 64 | Jul 2015actual | — | 2024-03-18 |
| Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)NCT00928577observationalThe percentage and rate per 1,000 of participants with subclinical, suspected, probable, or confirmed myopericarditis following vaccination with either ACAM2000® Smallpox vaccine or other vaccinia vaccine. | — | Completed | — | Smallpox | 14,108 | Dec 2014actual | — | 2024-04-04 |
| A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate VaccinesNCT01979406The safety, tolerability and immunogenicity of the Ad4 PA and Ad4 PA GPI vaccines across a range of dosages and schedules.Randomized · Quadruple-masked · Prevention | Phase 1 | Completed | Biological: AVA, Ad4-PA-1, Ad4-PA-GPI-1 | Anthrax Infection | 120 | Oct 2014actual | — | 2024-03-18 |
| A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose LevelsNCT01770743results2015-02-24Toxin Neutralizing Antibody (TNA) Level at Day 63Randomized · Triple-masked · Prevention | Phase 2 | Completed | Biological: AV7909, BioThrax | Anthrax | 168 | Feb 2014actual | — | 2024-03-18 |
| Ciprofloxacin BioThrax Co-Administration StudyNCT01753115results2014-11-19Ratios of Ciprofloxacin Area Under the Curve and Cmax (Day 5/Day 44)Randomized · Open-label · Treatment | Phase 2 | Completed | Biological: BioThrax · Drug: Ciprofloxacin | Anthrax | 154 | Aug 2013actual | — | 2025-06-15 |
| Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military PersonnelNCT01540929observationalThe percent of SF600 forms that did not clearly support the subsequent decision to vaccinate. | — | Completed | — | Smallpox | 5,001 | Sep 2012actual | — | 2024-03-18 |
| Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy AdultsNCT01263691results2014-08-20Incidence of Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Vaccination (Day 0)Randomized · Triple-masked · Prevention | Phase 1 | Completed | Biological: BioThrax, AV7909 Formulation 1, AV7909 Formulation 2, AV7909 Formulation 3, AV7909 Formulation 4 · Drug: Control | Bacillus Anthracis (Anthrax) Infection | 105 | May 2012actual | — | 2024-03-18 |
| Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy AdultsNCT01491607results2013-11-28Percentage of Subjects Achieving a TNA Response of a Predefined Threshold Value at Day 63 (5 Weeks Following the Third Vaccination on Day 28).Open-label · Treatment | Phase 3 | Completed | Biological: BioThrax | Anthrax | 200 | May 2012actual | — | 2024-04-09 |
| VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIVNCT01158157results2019-03-26Percent of Participants With Adverse Events Related to ACAM2000 Vaccine AdministrationOpen-label · Other | Phase 3 | Completed | Biological: ACAM2000 | Smallpox Vaccine Adverse Reaction | 25 | 2012-02-14actual | — | 2024-03-18 |
| Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1NCT01006798Safety, defined as the frequency and severity of vaccine-related reactogenicity events and reported AEsRandomized · Double-masked · Prevention | Phase 1 | Completed | Other: Placebo · Biological: Ad4-H5-Vtn, Sanofi Pasteur Influenza Virus Vaccine, H5N1 | Bird Flu, Influenza | 166 | Sep 2011actual | — | 2024-03-18 |
| Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)NCT01202695Safety assessmentsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: AVP-21D9, Placebo | Anthrax | 50 | Jun 2011actual | — | 2024-03-15 |
| Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)NCT01311674results2021-08-17Comparison Between Vaccination Schedules Using Day 210 Anti-HBs Antibody Titers AUC(0-t)Randomized · Open-label · Other | Phase 3 | Terminatedsponsor's stated reason: Prematurely terminated due to failure to meet study objectives. | Biological: hepatitis B vaccine, hepatitis B vaccine | Healthy Volunteers | 141 | 2011-03-11actual | — | 2024-03-18 |
| Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)NCT00845650results2018-06-13Number of Participants Reporting Adverse Events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Biological: AIGIV 3.5 mg/kg, Gamunex 90 mg/kg, AIGIV 7.0 mg/kg, Gamunex 180 mg/kg, AIGIV 14.0 mg/kg, Gamunex 360 mg/kg | Anthrax | 129 | Oct 2010actual | — | 2024-03-18 |
| Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB MuscleNCT00636519Nerve Conduction StudyRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Biological: Botulism Antitoxin Bivalent (Equine) Types A and B, Botulism Antitoxin Heptavalent (Equine) Types A-G | Healthy Volunteers | 36 | Oct 2009actual | — | 2024-03-18 |
| Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy AdultsNCT00679172results2017-06-07Number and Proportion of Subjects Reporting Suspected Unexpected Serious Adverse Reactions.Randomized · Triple-masked · Prevention | Phase 2 | Completed | Biological: Dose of 5.0 x 10^9 CFU (Cohort 1), Dose of 7.5 x 10^9 CFU (Cohort 2), Dose of 1.1 x 10^10 CFU (Cohort 3), Dose of of 1.7 x 10^10 CFU (Cohort 4) · Other: Placebo (Cohorts 1-4 pooled) | Typhoid | 187 | Dec 2008actual | — | 2024-04-09 |
| CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell LymphomaNCT00893516results2021-04-21Primary Outcome UnavailableRandomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Portfolio consolidation. | Biological: CHOP + CD4 · Drug: CHOP | T-cell Lymphoma | 5 | Oct 2008actual | — | 2024-04-09 |
| Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human SerumNCT00448253Anti-PA antibody and TNA for PK analyses.Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Biological: NP-015 | Symptoms of Inhalational Anthrax | 92 | Aug 2008actual | — | 2024-03-15 |
| Safety Study of 7 Botulinum Antitoxin Serotypes Derived From HorsesNCT00360737Subjects with adverse events over the course of the studyRandomized · Double-masked · Treatment | Phase 1 | Completed | Biological: Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE) | Healthy | 40 | Dec 2006actual | — | 2024-03-18 |
| HuMax-CD4 in Non-Cutaneous T-Cell LymphomaNCT00877656Efficacy as measured by survival and time to disease progressionRandomized · Open-label · Treatment | Phase 2/3 | Completed | Biological: HuMax-CD4 | T Cell Lymphoma | 21 | Jan 2006actual | — | 2024-03-18 |
| Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox VaccinationNCT00053495results2011-02-11Number of Participants Reporting Adverse Events of Severe Intensity Post-vaccination With ACAM2000 or Dryvax® Smallpox VaccineRandomized · Quadruple-masked · Prevention | Phase 2 | Completed | Biological: Vaccinia virus: ACAM2000 smallpox vaccine, vaccinia virus (calf lymph): Dryvax | Smallpox | 353 | Jun 2003actual | — | 2024-03-18 |
| Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated AdultsNCT00053482results2011-02-11The Neutralizing Antibody Response Titers Post-vaccination With ACAM2000 or Dryvax® Smallpox VaccineRandomized · Quadruple-masked · Prevention | Phase 2 | Completed | Biological: ACAM2000 Smallpox Vaccine, Vaccinia virus (calf lymph) smallpox vaccine: Dryvax® | Smallpox | 357 | Apr 2003actual | — | 2024-03-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19